The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Dextrose and Sodium Chloride
DEXTROSE MONOHYDRATE and SODIUM CHLORIDE · DEXTROSE MONOHYDRATE 5 g/100mL; SODIUM CHLORIDE .9 g/100mL · Injection, Solution · Intravenous · ICU Medical Inc.
NDC 00990-7941-03 · 24 POUCH in 1 CASE / 1 BAG in 1 POUCH / 500 mL in 1 BAG · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 63323-0870-74) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$0.0056per unit
middle half $0.0043–$0.0100 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
$0.0034–$0.0042
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
100%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 0%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 5 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$5.44
Reported to Texas DSHS · 2026 annual filing · Otsuka ICU Medical LLC
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 500 ML
$1.215
HCPCS J7042 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$1,280
247 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Otsuka ICU Medical LLCUnited Statesanalysis · label · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA017585
- TE code
- AP
- Approval date
- Jan 1, 1982
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of DEXTROSE MONOHYDRATE and SODIUM CHLORIDE (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Becton Dickinson And Company | DEXTROSE MONOHYDRATE 5 g/100mL; SODIUM CHLORIDE .9 g/100mL | Jul 15, 2026 | Sep 2, 2026 |
| Becton Dickinson And Company | DEXTROSE MONOHYDRATE 5 g/100mL; SODIUM CHLORIDE .45 g/100mL | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | DEXTROSE MONOHYDRATE 5 g/100mL; SODIUM CHLORIDE .225 g/100mL | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | DEXTROSE MONOHYDRATE 5 g/100mL; SODIUM CHLORIDE .3 g/100mL | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | DEXTROSE MONOHYDRATE 5 g/100mL; SODIUM CHLORIDE .45 g/100mL | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | DEXTROSE MONOHYDRATE 5 g/100mL; SODIUM CHLORIDE .9 g/100mL | Jul 15, 2026 | Sep 2, 2026 |
| ICU Medical Inc. | DEXTROSE MONOHYDRATE 5 g/100mL; SODIUM CHLORIDE .45 g/100mL | Jul 15, 2026 | Sep 2, 2026 |
| ICU Medical Inc. | DEXTROSE MONOHYDRATE 5 g/100mL; SODIUM CHLORIDE .225 g/100mL | Jul 15, 2026 | Sep 2, 2026 |
| ICU Medical Inc. | DEXTROSE MONOHYDRATE 5 g/100mL; SODIUM CHLORIDE .3 g/100mL | Jul 15, 2026 | Sep 2, 2026 |
| ICU Medical Inc. | DEXTROSE MONOHYDRATE 5 g/100mL; SODIUM CHLORIDE .9 g/100mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Dextrose and Sodium Chloride — NDC 00990-7941-03," retrieved September 3, 2026, https://drugdashboards.com/drug/00990794103.
Free to cite with attribution — see how the data is put together.